Treosulfan vs. Clofarabine-Based Conditioning
A Phase II Randomized Study to Assess Outcomes With Treosulfan-Based Versus Clofarabine-Based Conditioning in Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 80 patients (estimated)
- Sponsors
- Fred Hutchinson / University of Washington Cancer Consortium
- Collaborators
- Medexus Pharma, Inc.
- Tags
- Allogeneic Stem Cell Transplant, Antimetabolites, Chemotherapy, Radiation Therapy, Randomization
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1505
- NCT Identifier
- NCT04994808
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.